Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

The agency's website indicates HHS Secretary Robert F. Kennedy Jr. adopted the previous advisory panel's suggestion to expand access on June 25. AP also reports on FDA vaccine chief Vinay Prasad's ...